Literature DB >> 19883695

The evolution of HIV treatment guidelines: current state-of-the-art of ART.

Andrew R Zolopa1.   

Abstract

Expert panels have provided guidelines for the treatment of HIV infection for more than a decade. The guidelines have evolved rapidly reflecting the remarkable improvements in HIV therapeutics over this time. From guidelines based mostly on expert opinion - the current guidelines are now primarily evidence-based recommendations - which the vast majority of treating clinicians accept and follow. We will highlight the major guideline recommendations for initiation of antiretroviral therapy - focusing on new data for the asymptomatic patient and those presenting with acute AIDS-related opportunistic infections. Given the number of new drugs available, we are currently able to offer virtually all patients in practice - a fully suppressive regimen, even in patients with substantial multi-drug resistant HIV. A remarkable achievement since AZT was first introduced for the treatment of HIV. This article forms part of a special issue of Antiviral Research marking the 25th anniversary of antiretroviral drug discovery and development, vol. 85, issue 1, 2010. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19883695     DOI: 10.1016/j.antiviral.2009.10.018

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  29 in total

1.  A randomized controlled trial of Structural Ecosystems Therapy for HIV medication adherence and substance abuse relapse prevention.

Authors:  Daniel J Feaster; Victoria B Mitrani; Myron J Burns; Brian E McCabe; Ahnalee M Brincks; Allan E Rodriguez; Deshratn Asthana; Michael S Robbins
Journal:  Drug Alcohol Depend       Date:  2010-06-09       Impact factor: 4.492

2.  Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroAIDS therapeutics.

Authors:  Ari S Nowacek; JoEllyn McMillan; Reagan Miller; Alec Anderson; Barrett Rabinow; Howard E Gendelman
Journal:  J Neuroimmune Pharmacol       Date:  2010-03-17       Impact factor: 4.147

3.  Factors Associated With Retention Among Non-Perinatally HIV-Infected Youth in the HIV Research Network.

Authors:  Charles Farmer; Baligh R Yehia; John A Fleishman; Richard Rutstein; W Christopher Mathews; Ank Nijhawan; Richard D Moore; Kelly A Gebo; Allison L Agwu
Journal:  J Pediatric Infect Dis Soc       Date:  2014-10-19       Impact factor: 3.164

Review 4.  Hypersensitivity reactions to HIV therapy.

Authors:  Mas Chaponda; Munir Pirmohamed
Journal:  Br J Clin Pharmacol       Date:  2011-05       Impact factor: 4.335

5.  Which Patient Characteristics Among Cocaine Users with HIV Relate to Drug Use and Adherence Outcomes Following a Dual-Focused Intervention?

Authors:  Gaia Read; Karen S Ingersoll
Journal:  AIDS Behav       Date:  2016-03

Review 6.  Potential use of rapamycin in HIV infection.

Authors:  Marco Donia; James A McCubrey; Klaus Bendtzen; Ferdinando Nicoletti
Journal:  Br J Clin Pharmacol       Date:  2010-12       Impact factor: 4.335

7.  Simultaneous measurement of etravirine, maraviroc and raltegravir in pigtail macaque plasma, vaginal secretions and vaginal tissue using a LC-MS/MS assay.

Authors:  Anna K Blakney; Yonghou Jiang; Dale Whittington; Kim A Woodrow
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2016-05-02       Impact factor: 3.205

8.  Novel method for simultaneous quantification of phenotypic resistance to maturation, protease, reverse transcriptase, and integrase HIV inhibitors based on 3'Gag(p2/p7/p1/p6)/PR/RT/INT-recombinant viruses: a useful tool in the multitarget era of antiretroviral therapy.

Authors:  Jan Weber; Ana C Vazquez; Dane Winner; Justine D Rose; Doug Wylie; Ariel M Rhea; Kenneth Henry; Jennifer Pappas; Alison Wright; Nizar Mohamed; Richard Gibson; Benigno Rodriguez; Vicente Soriano; Kevin King; Eric J Arts; Paul D Olivo; Miguel E Quiñones-Mateu
Journal:  Antimicrob Agents Chemother       Date:  2011-05-31       Impact factor: 5.191

9.  Next-Generation Sequencing to Help Monitor Patients Infected with HIV: Ready for Clinical Use?

Authors:  Richard M Gibson; Christine L Schmotzer; Miguel E Quiñones-Mateu
Journal:  Curr Infect Dis Rep       Date:  2014-04       Impact factor: 3.725

10.  Mutations in multiple domains of Gag drive the emergence of in vitro resistance to the phosphonate-containing HIV-1 protease inhibitor GS-8374.

Authors:  Kirsten M Stray; Christian Callebaut; Bärbel Glass; Luong Tsai; Lianhong Xu; Barbara Müller; Hans-Georg Kräusslich; Tomas Cihlar
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.